ABSTRACT
The urea cycle protects the central nervous system from ammonia toxicity by converting ammonia to urea. N-acetylglutamate synthase (NAGS) catalyzes formation of N-acetylglutamate, an essential allosteric activator of carbamylphosphate synthetase 1. Enzymatic activity of mammalian NAGS doubles in the presence of L-arginine, but the physiological significance of NAGS activation by L-arginine has been unknown. The NAGS knockout (Nags-/-) mouse is an animal model of inducible hyperammonemia, which develops hyperammonemia without N-carbamylglutamate and L-citrulline supplementation (NCG + Cit). We used adeno associated virus (AAV) based gene transfer to correct NAGS deficiency in the Nags-/- mice, established the dose of the vector needed to rescue Nags-/- mice from hyperammonemia and measured expression levels of Nags mRNA and NAGS protein in the livers of rescued animals. This methodology was used to investigate the effect of L-arginine on ureagenesis in vivo by treating Nags-/- mice with AAV vectors encoding either wild-type or E354A mutant mouse NAGS (mNAGS), which is not activated by L-arginine. The Nags-/- mice expressing E354A mNAGS were viable but had elevated plasma ammonia concentration despite similar levels of the E354A and wild-type mNAGS proteins. The corresponding mutation in human NAGS (NP_694551.1:p.E360D) that abolishes binding and activation by L-arginine was identified in a patient with NAGS deficiency. Our results show that NAGS deficiency can be rescued by gene therapy, and suggest that L-arginine binding to the NAGS enzyme is essential for normal ureagenesis.
Subject(s)
Amino-Acid N-Acetyltransferase/genetics , Gene Transfer Techniques , Hyperammonemia/genetics , Urea Cycle Disorders, Inborn/genetics , Amino-Acid N-Acetyltransferase/metabolism , Animals , Arginine/metabolism , Arginine/pharmacology , Citrulline/metabolism , Citrulline/pharmacology , Dependovirus/genetics , Disease Models, Animal , Glutamates/metabolism , Glutamates/pharmacology , Humans , Hyperammonemia/metabolism , Hyperammonemia/pathology , Hyperammonemia/therapy , Mice , Mice, Knockout , Mutant Proteins/genetics , Urea/metabolism , Urea Cycle Disorders, Inborn/metabolism , Urea Cycle Disorders, Inborn/pathology , Urea Cycle Disorders, Inborn/therapyABSTRACT
OBJECTIVE: To study the prevalence, clinical and genetic characteristics of primary carnitine deficiency (PCD). METHODS: From January 2013 to December 2017, 720 667 newborns and their mothers were tested for PCD by tandem mass spectrometry. Potential mutations of carnitine transporter gene SLC22A5 among suspected PCD patients were analyzed. Dietary guidance and L-carnitine supplementation were provided to the parents. Growth and intelligence development were surveyed during follow-up. RESULTS: In total 21 neonates and 6 mothers were diagnosed with PCD, which yielded an incidence of 1 in 34 317. Eighteen SLC22A5 mutations were detected, which included 4 novel mutations, namely c.1484T>C, c.394-1G>T, c.431T>C and c.265-266insGGCTCGCCACC. Eighteen patients were found to carry compound heterozygous mutations and 3 have carried homozygous SLC22A5 mutations. Three mothers carried compound heterozygous mutations and 2 carried homozygous mutations. Common mutations included c.1400C>G (42.3%), c.760C>T (11.5%) and c.51C>G (7.7%). During the 8-42 month follow-up, neonates with PCD showed no clinical symptoms but normal growth. Blood level of free carnitine was raised in all mothers after the treatment. CONCLUSION: The incidence of neonatal PCD in Henan is 1 in 34 317, with the most common mutation being c.1400C>G. Above finding has enriched the spectrum of SLC22A5 gene mutations.
Subject(s)
Cardiomyopathies/genetics , Carnitine/deficiency , Hyperammonemia/genetics , Muscular Diseases/genetics , Solute Carrier Family 22 Member 5/genetics , Cardiomyopathies/epidemiology , Carnitine/administration & dosage , Carnitine/genetics , China , Female , Humans , Hyperammonemia/epidemiology , Infant, Newborn , Muscular Diseases/epidemiology , Mutation , Neonatal ScreeningABSTRACT
We report a case of sudden unexplained death in a young asymptomatic woman in whom postmortem genetic testing after a negative autopsy identified a homozygous pathogenic mutation in SLC22A5 which leads clinically to primary carnitine deficiency (PCD). Her brother was subsequently diagnosed clinically with short QT syndrome, received an implantable defibrillator, and was then found to carry the same pathogenic homozygous mutation and critically low levels of carnitine. His QT interval improved with the use of carnitine supplementation, highlighting the close relationship between electrophysiology and biochemistry, and the importance of postmortem genetic testing in the clinical management of surviving relatives.
Subject(s)
Cardiomyopathies/genetics , Carnitine/deficiency , Death, Sudden, Cardiac/etiology , Genetic Testing/methods , Hyperammonemia/genetics , Long QT Syndrome/genetics , Muscular Diseases/genetics , Mutation , Solute Carrier Family 22 Member 5/genetics , Adult , Autopsy , Cardiomyopathies/complications , Cardiomyopathies/metabolism , Carnitine/genetics , Carnitine/metabolism , DNA/genetics , Fatal Outcome , Female , Genetic Predisposition to Disease , Humans , Hyperammonemia/complications , Hyperammonemia/metabolism , Long QT Syndrome/etiology , Muscular Diseases/complications , Muscular Diseases/metabolism , Solute Carrier Family 22 Member 5/metabolismABSTRACT
BACKGROUND: Maternofetal carnitine transport through the placenta is the main route of fetal carnitine uptake. Decreased free carnitine levels discovered by newborn screening has identified many asymptomatic adult women with systemic primary carnitine deficiency (PCD). Here, we presented amplitude integrated electroencephalogram (aEEG) and magnetic resonance imaging (MRI) findings from a neonate with epilepsy whose mother was carnitine deficient. CASE PRESENTATION: A one-day-old female newborn was admitted after experiencing seizures for half a day; status epilepticus was found on the continuous normal voltage background pattern with immature sleep-wake cycling during aEEG monitoring. On T1-weighted, T2-weighted, FLAIR, and DWI head MRI, there were various degrees of hyperintense signals and diffusion restrictions in the deep white matter of the right hemisphere. Tandem mass spectrometry discovered carnitine deficiency on the second day, which elevated to normal by the 9th day before L-carnitine supplementation was started. The patient was treated with phenobarbital after admission. No further seizures were noted by day 5. It was confirmed that the patient's mother had a low level of serum-free carnitine. Gene analyses revealed that the newborn had heterozygote mutations on c.1400C > G of the SLC22A5 gene, and her mother had homozygous mutations on c.1400C > G. The patient had a good outcome at the 8-month follow up. CONCLUSIONS: Maternal carnitine deficiency that occurs during the perinatal period may manifest as secondary epilepsy with cerebral injury in neonates. The short-term neurodevelopmental outcomes were good. Early diagnosis of asymptomatic PCD in female patients can provide guidance for future pregnancies.
Subject(s)
Cardiomyopathies/complications , Carnitine/deficiency , Hyperammonemia/complications , Muscular Diseases/complications , Seizures/etiology , Brain/diagnostic imaging , Cardiomyopathies/diagnosis , Cardiomyopathies/genetics , Carnitine/blood , Carnitine/genetics , Electroencephalography , Female , Fetal Diseases/etiology , Humans , Hyperammonemia/diagnosis , Hyperammonemia/genetics , Infant, Newborn , Infant, Newborn, Diseases/diagnosis , Magnetic Resonance Imaging , Mothers , Muscular Diseases/diagnosis , Muscular Diseases/genetics , MutationABSTRACT
Systemic primary carnitine deficiency (CDSP) is a rare autosomal recessive disorder caused by a defect in plasma membrane uptake of carnitine due to SLC22A5 gene mutations. A nine-mo-old boy presented with hypertrophic cardiomyopathy, massive hepatomegaly and jaundice. Metabolic testing revealed very low free carnitine levels. Genetic analysis using Sanger sequencing method revealed compound heterozygous mutations in SLC22A5 gene, c. 1354 G > A (p. Glu452Lys, previously reported) and c.231_234del (novel frame-shift). Oral carnitine supplementation resulted in improved clinical outcome with ejection fraction to 75 % and normalization of liver size and enzymes after 3 mo.
Subject(s)
Cardiomyopathies/etiology , Carnitine/deficiency , Carnitine/therapeutic use , Hepatomegaly/etiology , Hyperammonemia/complications , Hyperammonemia/drug therapy , Muscular Diseases/complications , Muscular Diseases/drug therapy , Cardiomyopathies/complications , Cardiomyopathies/drug therapy , Cardiomyopathies/genetics , Carnitine/genetics , Humans , Hyperammonemia/genetics , Infant , Male , Muscular Diseases/geneticsABSTRACT
The authors present a case of carnitine transporter deficiency, which was unmasked after an episode of respiratory distress resistant to treatment with bronchodilators. Chest radiograph showed cardiomegaly; electrocardiogram showed left ventricular hypertrophy and echocardiography revealed dilated cardiomyopathy. Heart failure therapy was initiated and metabolic screening was requested, as family history was indicative of inborn errors of metabolism. Very low levels of free carnitine and carnitine esters in blood were found and genetic testing confirmed the diagnosis of carnitine transporter deficiency. After oral supplementation with L-carnitine, symptoms gradually ameliorated and heart function had fully recovered. Sequence analysis in the SLC22A5 gene revealed the missense mutation c.1319C > T (p.Th440Met) in homozygous state. Homozygous c.1319C > T (p.Th440Met) mutation has not been associated with a pure cardiac phenotype before.
Subject(s)
Cardiomyopathies/complications , Cardiomyopathies/diagnosis , Cardiomyopathy, Dilated/diagnosis , Cardiomyopathy, Dilated/etiology , Carnitine/deficiency , Hyperammonemia/complications , Hyperammonemia/diagnosis , Muscular Diseases/complications , Muscular Diseases/diagnosis , Cardiomyopathies/drug therapy , Cardiomyopathies/genetics , Cardiomyopathy, Dilated/drug therapy , Carnitine/genetics , Carnitine/therapeutic use , Child, Preschool , Diagnosis, Differential , Female , Humans , Hyperammonemia/drug therapy , Hyperammonemia/genetics , Muscular Diseases/drug therapy , Muscular Diseases/geneticsABSTRACT
Naringin, plant bioflavonoid extracted mainly from grapefruit and other related citrus species. This study was designed to assess the neuroprotective effect of naringin on ammonium chloride (NH4Cl) induced hyperammonemic rats. Experimental hyperammonemia was induced by intraperitonial injection (i.p) of NH4Cl (100mg/kg body weight (b.w.)) thrice a week for 8 consecutive weeks. Hyperammonemic rats were treated with naringin (80mg/kg b.w.) via oral gavage. Naringin administration drastically restored the levels of blood ammonia, plasma urea, nitric oxide (NO), glutamate, glutamine, lipid peroxidation, lipid profile, activities of liver marker enzymes, antioxidant status and sodium/potassium-ATPase (Na+/K+-ATPase). In addition, naringin supplementation reverted back the pathological changes of liver, brain and kidney tissues, the expressions of Glutamine synthetase (GS), Na+/K+-ATPase, neuronal nitric oxide (nNOS) and soluble guanylate cyclase (sGC) in hyperammonemic rats. Hence, this study suggested that nargingin exhibited their protective effect against NH4Cl induced toxicity via enhancing the activities of antioxidant enzymes and inhibiting the lipid peroxidation process. Take together, this study provides data that naingin effectively reduced neurotoxicity by attenuating hyperammonemia, suggesting that naringin act as a potential therapeutic agent to treat hyperammonemic rats.
Subject(s)
Ammonium Chloride , Cyclic GMP/metabolism , Flavanones/pharmacology , Glutamic Acid/blood , Hyperammonemia/drug therapy , Neuroprotective Agents/pharmacology , Neurotoxicity Syndromes/prevention & control , Nitric Oxide/blood , Ammonia/blood , Animals , Antioxidants/metabolism , Biomarkers/blood , Brain/drug effects , Brain/enzymology , Disease Models, Animal , Glutamate-Ammonia Ligase/genetics , Glutamate-Ammonia Ligase/metabolism , Hyperammonemia/blood , Hyperammonemia/chemically induced , Hyperammonemia/genetics , Kidney/drug effects , Kidney/enzymology , Lipid Peroxidation/drug effects , Lipids/blood , Liver/drug effects , Liver/enzymology , Male , Neurotoxicity Syndromes/blood , Neurotoxicity Syndromes/etiology , Neurotoxicity Syndromes/genetics , Nitric Oxide Synthase Type I/genetics , Nitric Oxide Synthase Type I/metabolism , Rats, Wistar , Signal Transduction/drug effects , Sodium-Potassium-Exchanging ATPase/genetics , Sodium-Potassium-Exchanging ATPase/metabolism , Soluble Guanylyl Cyclase/genetics , Soluble Guanylyl Cyclase/metabolism , Time FactorsABSTRACT
BACKGROUND: Short QT syndrome is associated with an increased risk of cardiac arrhythmias and unexpected sudden death. Until now, only mutations in genes encoding the cardiac potassium and calcium channels have been implicated in early T-wave repolarization. OBJECTIVE: The purpose of this study was to confirm a relationship between a short QT syndrome and carnitine deficiency. METHODS: We report 3 patients affected by primary systemic carnitine deficiency and an associated short QT syndrome. Ventricular fibrillation during early adulthood was the initial symptom in 1 case. To confirm the relationship between carnitine, short QT syndrome, and arrhythmias, we used a mouse model of carnitine deficiency induced by long-term subcutaneous perfusion of MET88. RESULTS: MET88-treated mice developed cardiac hypertrophy associated with a remodeling of the mitochondrial network. The continuous monitoring of electrocardiograms confirmed a shortening of the QT interval, which was negatively correlated with the plasma carnitine concentration. As in humans, such alterations coincided with the genesis of ventricular premature beats and ventricular tachycardia and fibrillation. CONCLUSION: Altogether, these results suggest that long-chain fatty acid metabolism influence the morphology and the electrical function of the heart.
Subject(s)
Arrhythmias, Cardiac , Cardiomyopathies , Carnitine/deficiency , Hyperammonemia , Muscular Diseases , Adult , Animals , Arrhythmias, Cardiac/diagnosis , Arrhythmias, Cardiac/etiology , Arrhythmias, Cardiac/physiopathology , Arrhythmias, Cardiac/prevention & control , Cardiomyopathies/complications , Cardiomyopathies/diagnosis , Cardiomyopathies/drug therapy , Cardiomyopathies/genetics , Cardiomyopathies/physiopathology , Carnitine/administration & dosage , Carnitine/blood , Carnitine/genetics , Child, Preschool , Echocardiography, Doppler/methods , Electrocardiography/methods , Electrophysiologic Techniques, Cardiac , Female , Humans , Hyperammonemia/complications , Hyperammonemia/diagnosis , Hyperammonemia/drug therapy , Hyperammonemia/genetics , Hyperammonemia/physiopathology , Infant , Male , Mice , Mice, Inbred C57BL , Mitochondria, Heart/metabolism , Mitochondria, Heart/pathology , Muscular Diseases/complications , Muscular Diseases/diagnosis , Muscular Diseases/drug therapy , Muscular Diseases/genetics , Muscular Diseases/physiopathology , Treatment OutcomeABSTRACT
Systemic primary carnitine deficiency is an autosomal recessive disorder caused by the deficiency of carnitine transporter. Main features are cardiomyopathy, myopathy and hypoglycemic encephalopathy. We report a Turkish case with a novel SLC22A5 gene mutation presented with a pure cardiac phenotype. During the 14-year follow-up study, cardiac functions were remained within a normal range with oral L-carnitine supplementation.
Subject(s)
Cardiomyopathies/genetics , Carnitine/deficiency , Carnitine/therapeutic use , Hyperammonemia/genetics , Muscular Diseases/genetics , Mutation , Organic Cation Transport Proteins/genetics , Adolescent , Cardiomyopathies/drug therapy , Carnitine/genetics , Child , Child, Preschool , Hormone Replacement Therapy , Humans , Hyperammonemia/drug therapy , Male , Muscular Diseases/drug therapy , Solute Carrier Family 22 Member 5 , TurkeyABSTRACT
Disorders of carnitine biosynthesis have recently been associated with neurodevelopmental syndromes such as autism spectrum disorder (ASD). A 4-year-old male with autism and two episodes of neurodevelopmental regression was identified to have a mutation in the TMLHE gene, which encodes the first enzyme in the carnitine biosynthesis pathway, and concurrent carnitine deficiency. Following carnitine supplementation, the patient's regression ended, and the boy started gaining developmental milestones. This case report suggests that deficits in carnitine biosynthesis may be responsible for some cases of regression in individuals with ASD, and that testing for the respective biochemical pathway should be considered. Furthermore, this case suggests that carnitine supplementation may be useful in treating (and potentially preventing) regressive episodes in patients with carnitine deficiency. Further work to better define the role of disorders of carnitine biosynthesis in autism spectrum disorder is warranted.
Subject(s)
Autism Spectrum Disorder/genetics , Autistic Disorder/genetics , Cardiomyopathies/genetics , Carnitine/deficiency , Hyperammonemia/genetics , Muscular Diseases/genetics , Carnitine/genetics , Child Development Disorders, Pervasive/genetics , Child, Preschool , Dietary Supplements , Humans , MaleABSTRACT
Glutamine synthetase (GS) deficiency is an ultra-rare inborn error of amino acid metabolism that has been described in only three patients so far. The disease is characterized by neonatal onset of severe encephalopathy, low levels of glutamine in blood and cerebrospinal fluid, chronic moderate hyperammonemia, and an overall poor prognosis in the absence of an effective treatment. Recently, enteral glutamine supplementation was shown to be a safe and effective therapy for this disease but there are no data available on the long-term effects of this intervention. The amino acid glutamine, severely lacking in this disorder, is central to many metabolic pathways in the human organism and is involved in the synthesis of nicotinamide adenine dinucleotide (NAD(+)) starting from tryptophan or niacin as nicotinate, but not nicotinamide. Using fibroblasts, leukocytes, and immortalized peripheral blood stem cells (PBSC) from a patient carrying a GLUL gene point mutation associated with impaired GS activity, we tested whether glutamine deficiency in this patient results in NAD(+) depletion and whether it can be rescued by supplementation with glutamine, nicotinamide or nicotinate. The present study shows that congenital GS deficiency is associated with NAD(+) depletion in fibroblasts, leukocytes and PBSC, which may contribute to the severe clinical phenotype of the disease. Furthermore, it shows that NAD(+) depletion can be rescued by nicotinamide supplementation in fibroblasts and leukocytes, which may open up potential therapeutic options for the treatment of this disorder.
Subject(s)
Amino Acid Metabolism, Inborn Errors/genetics , Glutamate-Ammonia Ligase/deficiency , Glutamine/blood , Hyperammonemia/genetics , NAD/blood , NAD/deficiency , B-Lymphocytes/cytology , Cell Culture Techniques , Dietary Supplements , Fibroblasts/cytology , Glutamate-Ammonia Ligase/genetics , Humans , Point MutationABSTRACT
Systemic primary carnitine deficiency (CDSP) is a rare autosomal recessive disorder that presents episodic periods of hypoketotic hypoglycemia. The main symptoms of CDSP are skeletal and cardiac myopathy. CDSP is caused by a defect in plasma membrane uptake of carnitine, ultimately caused by the SLC22A5 gene. We report the case of a Korean patient with CDSP. He had an abnormal free carnitine level of 5.56 µmol/L (reference range, RR 10.4~87.1 µmol/L) and a palmitoylcarnitine level of 0.27 µmol/L (RR 0.5~9.7 µmol/L) in a newborn screening test. The patient showed an ammonia level of 129.4 ug/dL (RR, 25~65 ug/dL), a lactate level of 4.5 mmol/L (RR, 0.5-2.2 mmol/L), and a free carnitine level of 10.3 µmol/L (RR, 36-74 µmol/L) in blood. After PCR-sequencing analysis of the SLC22A5 gene, the patient was found to be a compound heterozygote for c.506G>A (p.R169Q) and c.1400C>G (p.S467C) mutations. These missense mutations are reported previously. The patient was started on L-carnitine supplement after CDSP diagnosis. The patient was treated with L-carnitine to reach a normal free carnitine level and has remained asymptomatic up to the current age of 21 months. The plasma free carnitine level normalized to 66.6 µmol/L at 4 weeks after treatment. To the best of our knowledge, this is the first report of a CDSP patient confirmed by molecular genetic investigation.
Subject(s)
Cardiomyopathies/genetics , Hyperammonemia/genetics , Muscular Diseases/genetics , Mutation, Missense/genetics , Organic Cation Transport Proteins/genetics , Ammonia/blood , Base Sequence , Cardiomyopathies/blood , Cardiomyopathies/drug therapy , Carnitine/blood , Carnitine/deficiency , Carnitine/genetics , Carnitine/therapeutic use , Humans , Hyperammonemia/blood , Hyperammonemia/drug therapy , Infant, Newborn , Lactic Acid/blood , Male , Molecular Sequence Data , Muscular Diseases/blood , Muscular Diseases/drug therapy , Polymerase Chain Reaction , Republic of Korea , Sequence Analysis, DNA , Solute Carrier Family 22 Member 5 , Treatment OutcomeABSTRACT
OBJECTIVE: Many children were found to have low free carnitine level in blood by tandem mass spectrometry technology. In some of the cases the problems occurred secondary to malnutrition, organic acidemia and other fatty acid oxidation metabolic diseases, and some of cases had primary carnitine deficiency (PCD). In the present article, we discuss the diagnosis of PCD and evaluate the efficacy of carnitine in the treatment of PCD. METHOD: We measured the free carnitine (C0) and acylcarnitine levels in the blood of 270 000 neonates from newborns screening program and 12 000 children with suspected clinical inherited metabolic diseases by tandem mass spectrometry. The mutations of carnitine transporter protein were tested to the children with low C0 level and the diagnosis was made. The children with PCD were treated with 100 - 300 mg/kg of carnitine. RESULT: Seventeen children were diagnosed with PCD, 6 from newborn screening program and 11 from clinical patients. Mutations were found in all of them. The average C0 level [(2.9 ± 2.0) µmol/L] in patients was lower than the reference value (10 µmol/L), along with decreased level of different acylcarnitines. The clinical manifestations were diverse. For the 6 patients from newborn screening, 4 were asymptomatic, 1 showed hypoglycaemia and 1 showed movement intolerance from 2 years of age. For the 11 clinical patients, 8 showed hepatomegaly, 7 showed myasthenia, 6 showed cardiomyopathy, 1 showed chronic abdominal pain, and 1 showed restlessness and learning difficulty. Among these patients, 14 cases were treated with carnitine. Their clinical symptoms disappeared 1 to 3 months later. The C0 level in the blood rose to normal, with the average from (4.0 ± 2.7) µmol/L to (20.6 ± 8.3) µmol/L (P < 0.01). However, the level was still lower than the average level of healthy children [(27.1 ± 4.5) µmol/L, P < 0.01]. CONCLUSION: Seventeen patients were diagnosed with PCD by the test levels of free carnitine and acylcarnitines in blood with tandem mass spectrometry, and gene mutation test. Large dose of carnitine had a good effect in treatment of the PCD patients.
Subject(s)
Cardiomyopathies/diagnosis , Cardiomyopathies/drug therapy , Carnitine/analogs & derivatives , Carnitine/blood , Hyperammonemia/diagnosis , Hyperammonemia/drug therapy , Muscular Diseases/diagnosis , Muscular Diseases/drug therapy , Tandem Mass Spectrometry , Cardiomyopathies/genetics , Carnitine/deficiency , Carnitine/genetics , Child, Preschool , DNA Mutational Analysis , Female , Follow-Up Studies , Humans , Hyperammonemia/genetics , Infant , Infant, Newborn , Male , Muscular Diseases/genetics , Mutation , Neonatal Screening/methods , Organic Cation Transport Proteins/deficiency , Organic Cation Transport Proteins/genetics , Reference ValuesABSTRACT
The urea cycle consists of six consecutive enzymatic reactions that convert waste nitrogen into urea. Deficiencies of any of these enzymes of the cycle result in urea cycle disorders (UCDs), a group of inborn errors of hepatic metabolism that often result in life-threatening hyperammonemia. Argininosuccinate lyase (ASL) catalyzes the fourth reaction in this cycle, resulting in the breakdown of argininosuccinic acid to arginine and fumarate. ASL deficiency (ASLD) is the second most common UCD, with a prevalence of ~1 in 70,000 live births. ASLD can manifest as either a severe neonatal-onset form with hyperammonemia within the first few days after birth or as a late-onset form with episodic hyperammonemia and/or long-term complications that include liver dysfunction, neurocognitive deficits, and hypertension. These long-term complications can occur in the absence of hyperammonemic episodes, implying that ASL has functions outside of its role in ureagenesis and the tissue-specific lack of ASL may be responsible for these manifestations. The biochemical diagnosis of ASLD is typically established with elevation of plasma citrulline together with elevated argininosuccinic acid in the plasma or urine. Molecular genetic testing of ASL and assay of ASL enzyme activity are helpful when the biochemical findings are equivocal. However, there is no correlation between the genotype or enzyme activity and clinical outcome. Treatment of acute metabolic decompensations with hyperammonemia involves discontinuing oral protein intake, supplementing oral intake with intravenous lipids and/or glucose, and use of intravenous arginine and nitrogen-scavenging therapy. Dietary restriction of protein and dietary supplementation with arginine are the mainstays in long-term management. Orthotopic liver transplantation (OLT) is best considered only in patients with recurrent hyperammonemia or metabolic decompensations resistant to conventional medical therapy.
Subject(s)
Argininosuccinic Aciduria/diagnosis , Argininosuccinic Aciduria/genetics , Arginine/metabolism , Arginine/therapeutic use , Argininosuccinate Lyase/genetics , Argininosuccinic Acid/blood , Argininosuccinic Acid/metabolism , Argininosuccinic Acid/urine , Argininosuccinic Aciduria/therapy , Child, Preschool , Citrulline/blood , Cognition Disorders/enzymology , Cognition Disorders/genetics , Diet, Protein-Restricted , Fumarates/metabolism , Genetic Testing , Glucose/therapeutic use , Humans , Hyperammonemia/enzymology , Hyperammonemia/genetics , Hypertension/enzymology , Hypertension/genetics , Infant , Infant, Newborn , Lipids/therapeutic use , Liver Diseases/enzymology , Liver Diseases/genetics , Liver Transplantation , Neonatal Screening , Phenylbutyrates/therapeutic use , Sodium Benzoate/therapeutic useSubject(s)
Cardiomyopathies/drug therapy , Cardiomyopathy, Hypertrophic/drug therapy , Carnitine/administration & dosage , Hyperammonemia/drug therapy , Muscular Diseases/drug therapy , Adult , Cardiomyopathies/complications , Cardiomyopathies/genetics , Cardiomyopathy, Hypertrophic/etiology , Cardiomyopathy, Hypertrophic/genetics , Carnitine/deficiency , Carnitine/genetics , Dietary Supplements , Follow-Up Studies , Humans , Hyperammonemia/complications , Hyperammonemia/genetics , Male , Muscular Diseases/complications , Muscular Diseases/genetics , Pedigree , SiblingsABSTRACT
We report on two Aboriginal patients with the hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome. Both presented with acute hepatic failure with severe hypertransaminasemia and coagulopathy, prompting evaluation for emergent liver transplantation. The diagnosis of HHH syndrome was based on the presence of typical metabolic abnormalities. A protein-restricted diet and L-arginine or L-citrulline supplementation were immediately started, with rapid normalization of liver function test results and other biochemical abnormalities. Molecular analysis of the SLC25A15 gene showed that the two patients were homozygous for the common French Canadian mutation (F188Delta). The diagnosis of HHH syndrome should be considered in patients with unexplained fulminant hepatic failure. There does not appear to be a genotype-phenotype correlation for this presentation, inasmuch as the only other reported patient presenting with this picture had two different point mutations. Early identification and prompt treatment of these patients is crucial to avoid liver transplantation and can be life saving.
Subject(s)
Diet, Protein-Restricted , Hyperammonemia/complications , Liver Failure, Acute/etiology , Metabolism, Inborn Errors/complications , Point Mutation , Amino Acid Transport Systems, Basic , Citrulline/analogs & derivatives , Citrulline/blood , Citrulline/urine , Female , Humans , Hyperammonemia/blood , Hyperammonemia/genetics , Infant , Liver Transplantation , Metabolism, Inborn Errors/blood , Metabolism, Inborn Errors/genetics , Mitochondrial Membrane Transport Proteins , Ornithine/blood , Ornithine/urine , SyndromeABSTRACT
Two isoforms of the human ornithine carrier, ORC1 and ORC2, have been identified by overexpression of the proteins in bacteria and by study of the transport properties of the purified proteins reconstituted into liposomes. Both transport L-isomers of ornithine, lysine, arginine, and citrulline by exchange and by unidirectional mechanisms, and they are inactivated by the same inhibitors. ORC2 has a broader specificity than ORC1, and L- and D-histidine, L-homoarginine, and D-isomers of ornithine, lysine, and ornithine are all substrates. Both proteins are expressed in a wide range of human tissues, but ORC1 is the predominant form. The highest levels of expression of both isoforms are in the liver. Five mutant forms of ORC1 associated with the human disease hyperornithinemia-hyperammonemia-homocitrullinuria were also made. The mutations abolish the transport properties of the protein. In patients with hyperornithinemia-hyperammonemia-homocitrullinuria, isoform ORC2 is unmodified, and its presence compensates partially for defective ORC1.
Subject(s)
Carrier Proteins/biosynthesis , Carrier Proteins/chemistry , Citrulline/analogs & derivatives , Membrane Transport Proteins , Mitochondria/metabolism , Amino Acid Transport Systems, Basic , Arginine/chemistry , Biological Transport , Carrier Proteins/genetics , Citrulline/chemistry , Citrulline/urine , DNA, Complementary/metabolism , Electrophoresis, Polyacrylamide Gel , Humans , Hyperammonemia/genetics , Kinetics , Liposomes/metabolism , Liver/enzymology , Lysine/chemistry , Malates/chemistry , Models, Biological , Mutation , Ornithine/chemistry , Ornithine/metabolism , Phosphates/chemistry , Protein Folding , Protein Isoforms , Recombinant Proteins/chemistry , Reverse Transcriptase Polymerase Chain Reaction , Substrate Specificity , Time Factors , Tissue Distribution , Transcription, GeneticABSTRACT
An infant aged 3 days presented with hyperammonaemic coma and seizures, which were found to be a result of a urea-cycle defect. Haemofiltration, alternative pathway metabolites, and glucose and insulin failed to lower the plasma ammonia concentration below 2000 micromol/L. The infant was then cooled to a rectal temperature of 34 degrees C for 48 h and put on haemofiltration for 12 h. Plasma ammonia fell to around 100 micromol/L and remained at this concentration after haemofiltration. He roused from his coma, breathed spontaneously, and resumed bottle feeding. Hypothermia may be therapeutic in such instances of metabolic coma because it lowers the enzymatic rate of production of the toxin while non-enzymatic methods remove the toxin.